Simulations Plus

Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum

Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals.

Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15

Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance

Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit

Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT

Acquisition doubles the Company’s TAM to $8 billion

Expected to be accretive to fiscal 2025 EPS

Conference call at 5:00PM ET to discuss transaction

Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users

InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT™ platform, with the GastroPlus® and ADMET Predictor® modelling software offered by Simulations Plus.

Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals

Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Partnership will produce an enhanced, validated dermal PBBM/PBPK model to inform product development and bioequivalence decisions.

Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use.

Strategic investments in early-stage companies to drive innovation and collaboration

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.

New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models

Partnership aims to integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development

Amparo de la Peña, Vice President of Pharmacometrics at Simulations Plus, will join Jeff Sachs, Pavan Vaddady and Hao Zhu as new board members for 2024.

Fiscal 2023 revenue increased 11% year-over-year to $59.6 million
Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68
Simulations Plus to host its Investor Day on November 14, 2023